Premium
Identification of the human cytomegalovirus glycoprotein B gene and induction of neutralizing antibodies via its expression in recombinant vaccinia virus.
Author(s) -
Cranage M.P.,
Kouzarides T.,
Bankier A.T.,
Satchwell S.,
Weston K.,
Tomlinson P.,
Barrell B.,
Hart H.,
Bell S.E.,
Minson A.C.
Publication year - 1986
Publication title -
the embo journal
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 7.484
H-Index - 392
eISSN - 1460-2075
pISSN - 0261-4189
DOI - 10.1002/j.1460-2075.1986.tb04606.x
Subject(s) - biology , virology , vaccinia , poxviridae , recombinant dna , orthopoxvirus , human cytomegalovirus , virus , recombinant virus , cytomegalovirus , glycoprotein , neutralizing antibody , antibody , gene , gene expression , microbiology and biotechnology , herpesviridae , viral disease , genetics
A human cytomegalovirus (HCMV) glycoprotein gene with homology to glycoprotein B (gB) of herpes simplex virus and Epstein‐Barr virus and gpII of varicella zoster virus has been identified by nucleotide sequencing. The gene has been expressed in recombinant vaccinia virus and the gene product recognized by monoclonal antibodies and human immune sera. Rabbits immunized with the recombinant vaccinia virus produced antibodies that immunoprecipitate gB from HCMV‐infected cells and neutralize HCMV infectivity in vitro. These data demonstrate a role for this protein in future HCMV vaccines.